Novel vitamin D3 analog, 21-(3-methyl-3-hydroxy-butyl)-19-nor D3, that modulates cell growth, differentiation, apoptosis, cell cycle, and induction of PTEN in leukemic cells

Blood

Volumn 97, Issue 8, 2001, Pages 2427-2433

  Hisatake, J I ^a   O'Kelly, J ^a   Uskokovic, M R ^a   Tomoyasu, S ^a   Koeffler, H P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

21 (3 METHYL 3 HYDROXYBUTYL) 19 NORCOLECALCIFEROL; ANNEXIN; COLECALCIFEROL DERIVATIVE; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P27; RETINOIC ACID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL GROWTH; CONTROLLED STUDY; DOSE RESPONSE; DRUG STRUCTURE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION;

EID: 0035871888     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.8.2427     Document Type: Article

References (55)

1. Post-transcriptional stabilization underlies p53-independent induction of p21WAF1/CIP1/SDI1 in differentiating human leukemic cells
2. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells
3. Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells
4. Alterations of differentiation, clonal proliferation, cell cycle progression and bcl-2 expression in RAR alpha-altered sublines of HL-60
5. 1,25-dihydroxyvitamin D3: In vivo and in vitro effects on human preleukemic and leukemic cells
6. Induction of macrophage differentiation of human normal and leukemic myeloid stem cells by 1,25-dihydroxyvitamin D3 and its fluorinated analogues
7. A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia
8. Development of a novel 1,25(OH)2-vitamin D3 analog with potent ability to induce HL-60 cell differentiation without modulating calcium metabolism
9. 1,25(OH)2-16ene-vitamin D3 is potent antileukemic agent with low potential to cause hypercalcemia
10. 1 alpha,25-dihydroxy-16-ene-23-yne-26.27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat
11. Vitamin D3 analogs: Effect on leukemic clonal growth and differentiation, and on serum calcium levels
12. 19-norhexafluoride analogue of vitamin D3: A novel class of potent inhibitors of proliferation of human breast cell lines
13. 19-nor-26,27-bishomovitamin D3 analogs: A unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells
14. 5,6-trans-16-ene-vitamin D3: A new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells
15. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
16. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
17. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta
18. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines
19. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors
20. PTEN gene alterations in lymphoid neoplasms
21. Frequent inactivation of PTEN in prostate cancer cell lines and xenograffs
22. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies
23. Mutation analysis of PTEN/MMAC1 in acute myeloid leukemia
24. Pten is essential for embryonic development and tumour suppression
25. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppresser gene in mice
26. A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia
27. Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects
28. 20-epivitamin D3 analogues: A novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines
29. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway
30. The multiple roles of PTEN in tumor suppression
31. Phorbol ester effect on differentiation of human myeloid leukemia cell lines blocked at different stages of maturation
32. Characterisation of a novel analogue of 1alpha,25(OH)(2)-vitamin D(3) with two side chains: Interaction with its nuclear receptor and cellular actions
33. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin
34. 19-nor vitamin-D analogs: A new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines
35. Synergistic decrease of clonal proliferation, induction of differentiation, and apoptosis of acute promyelocytic leukemia cells after combined treatment with novel 20-epi vitamin D3 analogs and 9-cis retinoic acid
36. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53
37. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53
38. 3
39. 1,25-dihydroxyvitamm D(3)-induced retardation of the G(2)/M traverse is associated with decreased levels of p34(cdc2) in HL60 cells
40. Cellular survival: A play in three Akts
41. PTEN gene transfer in human malignant glioma: Sensitization to irradiation and CD95L-induced apoptosis
42. PTEN transcriptionally modulates c-myc gene expression in human breast carcinoma cells and is invotved in cell growth regulation
43. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN
44. Adenovirus-mediated delivery of the PTEN gene inhibits cell growth by induction of apoptosis in endometrial cancer
45. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death
46. Impaired Fas response and autoimmunity in Pten+/- mice
47. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway
48. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells
49. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells
50. Adenovirus-mediated gene transfer of MMAC1/PTEN to glioblastoma cells inhibits S phase entry by the recruitment of p27Kip1 into cyclin E/CDK2 complexes
51. PTEN modulates celt cycle progression and celt survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway
52. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells
53. Growth suppression of human ovarian cancer cells by adenovirus-mediated transfer of the PTEN gene
54. Cell cycle arrest and astrocytic differentiation resulting from PTEN expression in glioma cells
55. Restoration of wild-type PTEN expression leads to apoptosis, induces differentiation, and reduces telomerase activity in human glioma cells